| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/17/2002 | WO2002004510A2 Gtp-binding proteins |
| 01/17/2002 | WO2002004509A2 Gene expression, genome alteration and reporter expression in myofibroblasts and myofibroblast-like cells |
| 01/17/2002 | WO2002004508A1 Tumour-associated antigen (b345), characterised by an amino acid sequence as in seq. id. no. 4 |
| 01/17/2002 | WO2002004506A1 A new polypeptide- human rna binding protein 19 and the polynucleotide encoding it |
| 01/17/2002 | WO2002004503A1 A new polypeptide- human l1 factor orf2 reverse transcription-related protein 15 and the polynucleotide encoding it |
| 01/17/2002 | WO2002004502A1 A NEW POLYPEPTIDE- MURINE ZINC FINGER PROTEIN (Zfp-1)16 AND THE POLYNUCLEOTIDE ENCODING IT |
| 01/17/2002 | WO2002004500A1 A new polypeptide- human zinc finger protein fpm315-17 and the polynucleotide encoding it |
| 01/17/2002 | WO2002004499A1 Chemokine receptor modulators, production and use |
| 01/17/2002 | WO2002004493A2 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/17/2002 | WO2002004492A2 Herpes zinc finger motifs |
| 01/17/2002 | WO2002004491A2 Methods and compositions relating to muscle selective calcineurin interacting protein (mcip) |
| 01/17/2002 | WO2002004490A2 Lipid metabolism molecules |
| 01/17/2002 | WO2002004487A2 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
| 01/17/2002 | WO2002004486A2 Bi-functional fusion proteins from hirudin and tap |
| 01/17/2002 | WO2002004482A1 Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| 01/17/2002 | WO2002004480A2 Connective tissue growth factor-2 |
| 01/17/2002 | WO2002004479A1 TRANSFORMING GROWTH FACTOR BETA (TGF-β) BLOCKING AGENT-TREATED STEM CELL COMPOSITION AND METHOD |
| 01/17/2002 | WO2002004423A1 Thrombin inhibitors comprising an aminoisoquinoline group |
| 01/17/2002 | WO2002004028A1 Methods of modulating wound healing and angiogenesis |
| 01/17/2002 | WO2002004025A1 Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| 01/17/2002 | WO2002004024A1 Composition for the treatment of diabetes |
| 01/17/2002 | WO2002004021A1 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| 01/17/2002 | WO2002004016A1 Enteric preparations containing physiologically active peptides |
| 01/17/2002 | WO2002004015A1 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 01/17/2002 | WO2002004014A1 New class of bioactive glycoprotein |
| 01/17/2002 | WO2002004013A1 Remedies for bone diseases |
| 01/17/2002 | WO2002004012A1 Anhydrous pharmaceutical composition of vancomycin for topical use |
| 01/17/2002 | WO2002004011A1 Anti-hiv and anti-tumor peptides and fragments of lysozyme |
| 01/17/2002 | WO2002004010A2 Inhibition of tumor growth by a nematode anticoagulant protein |
| 01/17/2002 | WO2002004009A2 Method for treating cancer using an interleukin- 4 antagonist |
| 01/17/2002 | WO2002004008A2 Methods of therapy with thrombin derived peptides |
| 01/17/2002 | WO2002004005A2 Short peptides comprising histidine or alanine and their therapeutic use |
| 01/17/2002 | WO2002003972A2 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
| 01/17/2002 | WO2002003961A1 Microspheres and adjuvants for dna vaccine delivery |
| 01/17/2002 | WO2002003960A1 Particulate vectors for improving oral absorption of active principles |
| 01/17/2002 | WO2002003922A2 Synthetic peptide for neurological disorders |
| 01/17/2002 | WO2002003921A2 Bax fragment induced tumor cell death |
| 01/17/2002 | WO2002003914A2 Improved thyroid hormone formulations |
| 01/17/2002 | WO2002003911A2 Prevention and treatment of alzheimer's disease |
| 01/17/2002 | WO2002003910A2 Antibacterial, antioxidant, immunomoduling and anticancerogenic preparation and method for using said preparation |
| 01/17/2002 | WO2002003886A1 Treatment of human herpesviruses using hyperthermia |
| 01/17/2002 | WO2001079296B1 Humar emr2, a g-protein coupled receptor from the egf-tm7 family |
| 01/17/2002 | WO2001078693A3 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
| 01/17/2002 | WO2001072962A3 Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 01/17/2002 | WO2001062786A3 Tlp peptides and dna sequences coding the same |
| 01/17/2002 | WO2001056595A3 Wound healing compositions and methods using tropoelastin and lysyl oxidase |
| 01/17/2002 | WO2001054681A8 Composition for treatment of stress |
| 01/17/2002 | WO2001054651A3 Modulation of gene expression in formation of fatty atherosclerotic lesions |
| 01/17/2002 | WO2001052791A3 Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents |
| 01/17/2002 | WO2001049838A3 Cis-acting regulatory nucleic acid sequences in the parathyroid hormone 3'-untranslated region |
| 01/17/2002 | WO2001049741A3 A process for isolation of osteopontin from milk |
| 01/17/2002 | WO2001049722A3 New actinobacillus pleuropneumoniae outer membrane protein and its uses |
| 01/17/2002 | WO2001049249A3 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| 01/17/2002 | WO2001047950A3 Basolateral sorting signal based on scf peptide and inhibitors thereof |
| 01/17/2002 | WO2001047543A3 Activation and inhibition of the immune system |
| 01/17/2002 | WO2001046125A3 Cd45 inhibitors |
| 01/17/2002 | WO2001044448A3 Human oxidoreductase proteins |
| 01/17/2002 | WO2001044291A3 Polynucleotid encoding the rg1 polypeptide |
| 01/17/2002 | WO2001043765A3 Method for localized administration of fibrinolytic metalloproteinases |
| 01/17/2002 | WO2001041782A3 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 01/17/2002 | WO2001040446A3 Pour-on formulations |
| 01/17/2002 | WO2001037847A3 Nontoxic vernix compositions and method of producing |
| 01/17/2002 | WO2001036461A3 Compositions and methods for regulating tumor-associated antigen expression |
| 01/17/2002 | WO2001035977A3 Attenuation of tumor growth, metastasis and angiogenesis by use of chondroitin sulfate degrading enzymes |
| 01/17/2002 | WO2001034769A3 24 human secreted proteins |
| 01/17/2002 | WO2001034178A3 Methods and compositions for treatment of traumatic brain injury |
| 01/17/2002 | WO2001034175A3 Methods of treating inflammatory bowel disease using cholera toxin b subunit |
| 01/17/2002 | WO2001032696A3 Traf family proteins |
| 01/17/2002 | WO2001031051A3 Antisense modulation of protein kinase c-theta expression |
| 01/17/2002 | WO2001030362A3 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 01/17/2002 | WO2001027290A3 Aortic carboxypeptidase-like protein and nucleic acids encoding same |
| 01/17/2002 | WO2001025429A3 Hepatoma-derived growth factor-like proteins, polynucleotides encoding them and methods of use |
| 01/17/2002 | WO2001023589A3 23431, a novel human ubiquitin protease |
| 01/17/2002 | WO2001022972A3 Immunostimulatory nucleic acids |
| 01/17/2002 | WO2001021656A3 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| 01/17/2002 | WO2001021259A3 Use and compositions for treating platelet-related disorders using anagrelide |
| 01/17/2002 | WO2001019305A8 Water absorbent keratin and gel formed therefrom |
| 01/17/2002 | WO2001016377A3 Diagnostics and therapeutics for osteoporosis |
| 01/17/2002 | WO2001016293A3 Dna encoding the human serine protease t |
| 01/17/2002 | WO2001013117A3 Proteins, genes and their use for diagnosis and treatment of breast cancer |
| 01/17/2002 | WO2001012598A3 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 01/17/2002 | WO2001012171A3 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| 01/17/2002 | WO2001010468A3 Drug-carrier complexes and methods of use thereof |
| 01/17/2002 | WO2001007471A3 Cell cycle and proliferation proteins |
| 01/17/2002 | WO2001001786A3 Methods and means for producing improved dairy products |
| 01/17/2002 | WO2000078971A3 Atp binding cassette transporter protein abc1 popypeptides |
| 01/17/2002 | WO2000078953A3 Human transport proteins |
| 01/17/2002 | WO2000078952A3 Human rna metabolism proteins (rmep) |
| 01/17/2002 | WO2000077192A9 Reg-binding protein |
| 01/17/2002 | WO2000068249B1 Novel g-protein modulator (gpm) proteins and nucleic acid molecules and uses therefor |
| 01/17/2002 | WO2000060077A3 Compounds for therapy and diagnosis of lung cancer and methods for their use |
| 01/17/2002 | WO2000025798A8 Treatment of parkinson's disease with oligonucleotides |
| 01/17/2002 | US20020007173 Method of inducing a CTL response |
| 01/17/2002 | US20020007052 Point mutations; genetic engineering; hybridization |
| 01/17/2002 | US20020007047 Polypeptide; for use in the diagnosis and treatment of inflammation, cancer, immunological defects and arthritis |
| 01/17/2002 | US20020007046 Polypeptides for use in the diagnosis, prevention and treatment of cancer and immunological defects |
| 01/17/2002 | US20020006943 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 01/17/2002 | US20020006915 Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation |
| 01/17/2002 | US20020006914 Enhancing the sensitivity of tumor cells to therapies |
| 01/17/2002 | US20020006912 Suppression of nuclear factor-kappab dependent processes using oligonucleotides |